Bayer
Whippany
New Jersey
United States
852 articles about Bayer
-
Bayer Opens First Co.Lab Life Science Incubator in Cambridge
5/4/2023
Bayer AG announced the inauguration of its new life science incubator dubbed “Co.Lab Cambridge” located in Kendall Square in Cambridge, U.S. Bayer’s Co.Lab Cambridge is specifically designed to support cutting-edge cell and gene therapies entrepreneurs with access to Bayer’s enterprise wide expertise in addition to state-of-the-art laboratory and office space.
-
TAAV launches new corporate brand as a reflection of its transformation
5/2/2023
TAAV Biomanufacturing Solutions S.L.U. presents a new brand that supports the company's transformation and purpose, which is to be the DNA manufacturing partner of choice for developers of recombinant adeno-associate virus technologies and thus become a fundamental part of the gene therapy industry.
-
Bayer Announces New Strategic Collaboration with New Jersey’s Leading Polytechnic Universities to Cultivate Data Science Talent in Region
4/24/2023
Today the Consumer Health North America division of Bayer announced a new strategic collaboration with two of New Jersey’s leading polytechnic universities – New Jersey Institute of Technology (NJIT) and Stevens Institute of Technology (Stevens).
-
Astepro® Allergy Partners with Meghann Fahy to Help Allergy Sufferers Conquer Allergies, Love & Spontaneity Fast
3/30/2023
No one feels sexy when spring allergies hit. Introducing Astepro® Allergy – the only long-lasting nasal spray that starts working in 30 minutes, so allergy sufferers can relieve their allergy symptoms and be more spontaneous in their romantic pursuits.
-
Bayer Launches New Collaboration With Oerth Bio To Further Advance Innovations in Crop Protection
3/28/2023
Bayer and the agricultural biotech company Oerth Bio announced a new collaboration seeking to develop the next generation of more sustainable crop protection products.
-
Fruit Logistica 2023: Bayer Focuses on Partnerships, Sustainability, and Innovation
3/23/2023
At this year's Fruit Logistica taking place in Berlin from February 8-10 Bayer highlights its solutions towards regenerative agriculture, meaning the balance between productivity outcomes and environmental protection, while supporting the needs of society and farmers.
-
Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer
3/23/2023
Bayer further expands the global clinical development program for NUBEQA® (darolutamide) in prostate cancer.
-
Darolutamide approved for additional prostate cancer indication in China
3/20/2023
The Chinese National Medical Products Administration has approved the oral androgen receptor inhibitor darolutamide in combination with docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer.
-
Bayer and Kimitec Join Forces To Bring the Next Generation of Biologicals to Millions of Growers Worldwide
3/17/2023
Bayer and Kimitec announced a new strategic partnership focused on accelerating the development and commercialization of biological crop protection solutions and biostimulants.
-
Bayer plans to substantially increase investment in U.S.-based pharmaceutical R&D, earmarking $1 billion to invest stateside in 2023.
-
AskBio Announces Gustavo Pesquin as New CEO
3/9/2023
Asklepios BioPharmaceutical, Inc., a wholly owned and independently operated subsidiary of Bayer AG, announced that Gustavo Pesquin will become the company's next Chief Executive Officer as of March 11, 2023.
-
Bayer To Distribute Pheromone-Based Biological Crop Protection Solutions From M2i Group
3/8/2023
Bayer announced a partnership with French company M2i Group to supply fruit and vegetable growers around the world with pheromone-based biological crop protection products.
-
Darolutamide receives EU approval for additional indication in prostate cancer
3/1/2023
The European Commission has granted marketing authorisation in the European Union for darolutamide, an oral androgen receptor inhibitor, plus androgen deprivation therapy in combination with docetaxel, for the treatment of patients with metastatic hormone-sensitive prostate cancer.
-
Amid mounting pressure from investors and shareholders, Bayer’s supervisory board unanimously appointed outsider Bill Anderson as its new CEO.
-
Bayer Announces First Patients Enrolled in Global Phase III Studies for Investigational Oral FXIa Inhibitor Asundexian
2/8/2023
Bayer today announced the first patients have been enrolled in the initial trials for its OCEANIC clinical trial program, designed to explore the use of asundexian (BAY2433334).
-
Bayer Announces Full Commercialization of ThryvOn™ Technology in the U.S., a Unique Cotton Biotech Trait Set to Launch for 2023 Growing Season
2/7/2023
In time for the 2023 cotton planting season, Bollgard® 3 ThryvOn™ cotton with XtendFlex® Technology is now commercially available.
-
Bayer Appoints Ben Kampelman as Vice President of Communications for Crop Science North America
1/24/2023
Bayer today announced that Ben Kampelman, formerly Director, Strategic Communications for Crop Science North America, has been appointed to the role of Vice President of Communications, Crop Science North America.
-
Bayer Acquires Blackford Analysis Ltd. Bolstering the Company’s Position in Digital Medical Imaging
1/18/2023
Bayer announced the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd.
-
Evogene to Receive $3.5 million Payment Related to Patent Portfolio under its Existing Seed Traits Collaboration with Bayer
12/8/2022
Evogene Ltd. announced today that Bayer will pay Evogene an amount of $3.5 million under their joint seed traits collaboration agreement.
-
Bayer Launches Industry-First Public Database Listing Company’s Science Collaborations and Partnerships in the U.S.
12/6/2022
Bayer announced the U.S. launch of the Bayer Science Collaboration Explorer as part of its ongoing efforts to enhance public trust in scientific innovations, processes, and R&D activities.